1. Home
  2. RYTM vs CCS Comparison

RYTM vs CCS Comparison

Compare RYTM & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • CCS
  • Stock Information
  • Founded
  • RYTM 2008
  • CCS 2000
  • Country
  • RYTM United States
  • CCS United States
  • Employees
  • RYTM N/A
  • CCS N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • CCS Homebuilding
  • Sector
  • RYTM Health Care
  • CCS Consumer Discretionary
  • Exchange
  • RYTM Nasdaq
  • CCS Nasdaq
  • Market Cap
  • RYTM 3.2B
  • CCS 2.7B
  • IPO Year
  • RYTM 2017
  • CCS 2014
  • Fundamental
  • Price
  • RYTM $58.16
  • CCS $59.68
  • Analyst Decision
  • RYTM Strong Buy
  • CCS Buy
  • Analyst Count
  • RYTM 12
  • CCS 4
  • Target Price
  • RYTM $73.58
  • CCS $104.00
  • AVG Volume (30 Days)
  • RYTM 795.0K
  • CCS 522.0K
  • Earning Date
  • RYTM 05-06-2025
  • CCS 04-23-2025
  • Dividend Yield
  • RYTM N/A
  • CCS 1.89%
  • EPS Growth
  • RYTM N/A
  • CCS 29.19
  • EPS
  • RYTM N/A
  • CCS 10.40
  • Revenue
  • RYTM $130,126,000.00
  • CCS $4,398,288,000.00
  • Revenue This Year
  • RYTM $45.46
  • CCS $11.95
  • Revenue Next Year
  • RYTM $63.04
  • CCS $7.41
  • P/E Ratio
  • RYTM N/A
  • CCS $5.91
  • Revenue Growth
  • RYTM 68.06
  • CCS 19.12
  • 52 Week Low
  • RYTM $35.17
  • CCS $55.85
  • 52 Week High
  • RYTM $68.58
  • CCS $108.42
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.62
  • CCS 33.97
  • Support Level
  • RYTM $45.91
  • CCS $55.85
  • Resistance Level
  • RYTM $63.11
  • CCS $66.99
  • Average True Range (ATR)
  • RYTM 3.46
  • CCS 3.21
  • MACD
  • RYTM 0.29
  • CCS -0.76
  • Stochastic Oscillator
  • RYTM 36.33
  • CCS 25.11

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About CCS Century Communities Inc.

Century Communities Inc is a construction company that focuses on the residential market. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its own sales representatives and independent real estate brokers. It also advertises directly to potential homebuyers through the Internet, newspapers, and trade publications. The company generates the majority revenue from the Mountain segment.

Share on Social Networks: